Live Quote · NASDAQFATEHealthcare· Biotechnology

Fate Therapeutics, Inc.

$2.92 3.31%($-0.10)
TickerSpark Score
61/100
Mixed
47
Valuation
20
Profitability
55
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FATE research report →

52-Week Range87% of range
Low
$0.91
Current
$2.92
High
$3.21
Company Overviewwww.fatetherapeutics.com

About the company

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe.

CEO
Bahram Valamehr
IPO
2013
Employees
181
HQ
San Diego, CA, US

Price Chart

+160.71% · this period
$3.02$1.97$0.92Jul 02Dec 31Jul 02
Valuation
Market Cap
$340.35M
P/E
-2.68
P/S
53.89
P/B
1.95
EV/EBITDA
-3.22
Div Yield
0.00%
Profitability
Gross Margin
-415.79%
Op Margin
-2207.47%
Net Margin
-2056.79%
ROE
-58.89%
ROIC
-53.84%
Growth & Income
Revenue
$6.65M · -51.24%
Net Income
$-136,315,000 · 26.82%
EPS
$-1.15 · 29.88%
Op Income
$-147,704,000
FCF YoY
9.36%
Performance & Tape
52W High
$3.21
52W Low
$0.91
50D MA
$2.05
200D MA
$1.41
Beta
2.52
Avg Volume
3.81M

Get TickerSpark's AI analysis on FATE

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 12, 26Redmile Group, LLCother87,900
Jun 12, 26Lee Michael Stewartother87,900
Jun 12, 26Xu Yuanother87,900
Jun 12, 26Jooss Karinother87,900
Jun 12, 26EPSTEIN ROBERT Sother87,900
Jun 12, 26Agarwal Shefaliother87,900
Jun 12, 26ABERNETHY MATTother87,900
Jun 12, 26RASTETTER WILLIAM Hother87,900
Jun 12, 26Hamill Lauraother175,800
Jun 12, 26Hamill Lauraother0
Coverage · FATE

Our FATE coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on FATE yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate FATE report →
Internal Compare

Similar companies

Peers in the same neighborhood.